So far this year, i.e, January to June, only 12 novel drugs have been approved compared to 20 during the same period last year. Now, let's take a look at the biotech stocks awaiting the U.S. regulatory decision in July.
from RTT - Biotech https://ift.tt/2YfSXpK
via IFTTT
No comments:
Post a Comment